Methylation-associated silencing of microRNA-129-3p promotes epithelial-mesenchymal transition, invasion and metastasis of hepatocelluar cancer by targeting Aurora-A
- PMID: 27793005
- PMCID: PMC5363640
- DOI: 10.18632/oncotarget.12870
Methylation-associated silencing of microRNA-129-3p promotes epithelial-mesenchymal transition, invasion and metastasis of hepatocelluar cancer by targeting Aurora-A
Abstract
Metastasis and recurrence has become one major obstacle for further improving the survival of hepatocelluar cancer (HCC) patients. Therefore, it is critical to elucidate the mechanisms involved in HCC metastasis. This study aimed to investigate the roles of microRNA (miR)-129-3p in HCC metastasis and its possible molecular mechanisms. By using microarray analysis to compare levels of different miRNAs in HCC tissues with or without lymph node metastasis (LNM), we showed that HCC tissues with LNM had reduced levels of miR-129-3p, which was related to its promoter hypermethylation and correlated with tumor metastasis, recurrence and poor prognosis. Gain - and loss - of - function assays indicated that re-expression of miR-129-3p could reverse epithelial-mesenchymal transition (EMT), and reduce in vitro invasion and in vivo metastasis of HCC cells. Aurora-A, a serine/threonine protein kinase, was identified as a direct target of miR-129-3p. Knockdown of Aurora-A phenocopied the effect of miR-129-3p overexpression on HCC metastasis. In addition, Aurora-A upregulation could partially rescue the effect of miR-129-3p. We further demonstrated that activation of PI3K/Akt and p38-MAPK signalings were involved in miR-129-3p-mediated HCC metastasis. These findings suggest that methylation-mediated miR-129-3p downregulation promotes EMT, in vitro invasion and in vivo metastasis of HCC cells via activation of PI3K/Akt and p38-MAPK signalings partially by targeting Aurora-A. Therefore, miR-129-3p may be a novel prognostic biomarker and potential therapeutic target for HCC.
Keywords: Aurora-A; epithelial-mesenchymal transition; hepatocelluar cancer; metastasis; miR-129-3p.
Conflict of interest statement
The authors declare no conflicts of interest.
Figures









Similar articles
-
MicroRNAs Involved in Metastasis of Hepatocellular Carcinoma: Target Candidates, Functionality and Efficacy in Animal Models and Prognostic Relevance.Cancer Genomics Proteomics. 2020 Jan-Feb;17(1):1-21. doi: 10.21873/cgp.20163. Cancer Genomics Proteomics. 2020. PMID: 31882547 Free PMC article. Review.
-
MicroRNA-451: epithelial-mesenchymal transition inhibitor and prognostic biomarker of hepatocelluar carcinoma.Oncotarget. 2015 Jul 30;6(21):18613-30. doi: 10.18632/oncotarget.4317. Oncotarget. 2015. PMID: 26164082 Free PMC article.
-
miR-187-3p inhibits the metastasis and epithelial-mesenchymal transition of hepatocellular carcinoma by targeting S100A4.Cancer Lett. 2016 Oct 28;381(2):380-90. doi: 10.1016/j.canlet.2016.08.011. Epub 2016 Aug 17. Cancer Lett. 2016. PMID: 27544906
-
MicroRNA-1296 inhibits metastasis and epithelial-mesenchymal transition of hepatocellular carcinoma by targeting SRPK1-mediated PI3K/AKT pathway.Mol Cancer. 2017 Jun 12;16(1):103. doi: 10.1186/s12943-017-0675-y. Mol Cancer. 2017. PMID: 28606154 Free PMC article.
-
The Role of the MiR-181 Family in Hepatocellular Carcinoma.Cells. 2024 Jul 31;13(15):1289. doi: 10.3390/cells13151289. Cells. 2024. PMID: 39120319 Free PMC article. Review.
Cited by
-
miR-129-2-3p directly targets SYK gene and associates with the risk of ischaemic stroke in a Chinese population.J Cell Mol Med. 2019 Jan;23(1):167-176. doi: 10.1111/jcmm.13901. Epub 2018 Nov 29. J Cell Mol Med. 2019. PMID: 30499219 Free PMC article.
-
MiR-129-5p inhibits liver cancer growth by targeting calcium calmodulin-dependent protein kinase IV (CAMK4).Cell Death Dis. 2019 Oct 17;10(11):789. doi: 10.1038/s41419-019-1923-4. Cell Death Dis. 2019. PMID: 31624237 Free PMC article.
-
Roles of GSK-3 and microRNAs on epithelial mesenchymal transition and cancer stem cells.Oncotarget. 2017 Feb 21;8(8):14221-14250. doi: 10.18632/oncotarget.13991. Oncotarget. 2017. PMID: 27999207 Free PMC article. Review.
-
Targeted MicroRNA Profiling in Gastric Cancer with Clinical Assessement.Balkan J Med Genet. 2022 Jun 5;24(2):55-64. doi: 10.2478/bjmg-2021-0022. eCollection 2021 Nov. Balkan J Med Genet. 2022. PMID: 36249523 Free PMC article.
-
MicroRNAs Involved in Metastasis of Hepatocellular Carcinoma: Target Candidates, Functionality and Efficacy in Animal Models and Prognostic Relevance.Cancer Genomics Proteomics. 2020 Jan-Feb;17(1):1-21. doi: 10.21873/cgp.20163. Cancer Genomics Proteomics. 2020. PMID: 31882547 Free PMC article. Review.
References
-
- Jemal A, Siegel R, Xu J, Ward E. Cancer statistics, 2010. CA Cancer J Clin. 2010;60:277–300. - PubMed
-
- Zhou XD. Recurrence and metastasis of hepatocellular carcinoma: progress and prospects. Hepatobiliary Pancreat Dis Int. 2002;1:35–41. - PubMed
-
- Chen PY, Meister G. microRNA-guided posttranscriptional gene regulation. Biol Chem. 2005;386:1205–1218. - PubMed
-
- Li C, Hashimi SM, Good DA, Cao S, Duan W, Plummer PN, Mellick AS, Wei MQ. Apoptosis and microRNA aberrations in cancer. Clin Exp Pharmacol Physiol. 2012;39:739–746. - PubMed
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Miscellaneous